Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With Psoriasis

• Status: Recruiting
• Trial end date: 2026-07-26
• Target enrollment: 0
• Participant gender: All

Summary

The main purpose of this study is to characterize the long-term safety and efficacy of the drug Deucravacitinib (BMS-986165) in patients who have been previously enrolled in an applicable Phase 3 psoriasis study.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bristol-Myers Squibb
• Treatments: BMS-986165

Criteria

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit: www.BMSStudyConnect.com

Inclusion Criteria:

• Completion of the protocol-required treatment period in an applicable study of BMS-986165 in moderate-to-severe psoriasis

• Women must not be pregnant, lactating, or breastfeeding

Exclusion Criteria:

• Any disease or medical condition that the investigator feels that would make the patient unsuitable for this study.

• To be eligible for the study, a participant must not have active signs or symptoms of tuberculosis (TB) as judged by the investigator.

Other protocol-defined inclusion/exclusion criteria apply